SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 21.04 |
| Enterprise Value ($M) | 14.19 |
| Book Value ($M) | 6.76 |
| Book Value / Share | 0.35 |
| Price / Book | 3.11 |
| NCAV ($M) | 5.81 |
| NCAV / Share | 0.30 |
| Price / NCAV | 3.62 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -1.36 |
| Return on Assets (ROA) | -1.48 |
| Return on Equity (ROE) | -1.53 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 4.24 |
| Current Ratio | 4.24 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 7.72 |
| Assets | 8.68 |
| Liabilities | 1.92 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.46 |
| Operating Income | -5.70 |
| Net Income | -5.80 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -4.96 |
| Cash from Investing | -0.19 |
| Cash from Financing | 10.32 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Invenomic Capital Management LP | 4.70 | -22.45 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 15,028 | 94,296 | 15.94 | |
| 35,802 | 160,661 | 22.28 | |
| 31,481 | 80,735 | 38.99 | |
| 40,515 | 92,567 | 43.77 | |
| 39,086 | 122,873 | 31.81 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| KRRO – Korro Bio, Inc. | KTTA – Pasithea Therapeutics Corp. |
| KZR – Kezar Life Sciences, Inc. | LFVN – LifeVantage Corporation |
| LGVN – Longeveron Inc. |
Financial data and stock pages provided by
Fintel.io